Other Publication Details
Mandatory Fields
Reviews
Masterson, C;Jerkic, M;Curley, GF;Laffey, JG
2015
February
Mesenchymal stromal cell therapies: potential and pitfalls for ARDS
Published
1
Optional Fields
ACUTE LUNG INJURY RESPIRATORY-DISTRESS-SYNDROME UMBILICAL-CORD BLOOD HUMAN BONE-MARROW EPITHELIAL FLUID TRANSPORT KERATINOCYTE GROWTH-FACTOR TIDAL VOLUME VENTILATION ADULT STEM-CELLS INTRATRACHEAL TRANSPLANTATION INTRAPULMONARY DELIVERY
Mesenchymal stem/stromal cells (MSCs) offer considerable promise as a novel therapeutic strategy for acute respiratory distress syndrome (ARDS). MSCs may be able to "reprogramme" the immune response to reduce destructive inflammatory elements while preserving the host response to pathogens. In addition, MSCs may be able to enhance the repair and resolution of lung injury. Resolution of ARDS is impeded by destruction of the integrity of the epithelial barrier, which inhibits alveolar fluid clearance and depletes surfactant. MSCs appear to restore epithelial and endothelial function, via both paracrine and cell contact dependent effects. ARDS is frequently a component of a generalized process resulting in dysfunction and failure of multiple organs. MSCs have been demonstrated to decrease injury and/or restore function in other organs, including the kidney, liver and heart. MSCs may directly attenuate bacterial sepsis, the commonest and most severe cause of ALI/ARDS. The fact that MSCs are in clinical studies for a wide range of disease processes is a clear advantage for translating MSCs to clinical testing in patients with ARDS. However, some important knowledge gaps exist that may impede clinical translation. The ultimate success of MSCs as a therapy for patients with ARDS will likely be dependent on a greater knowledge of their mechanisms of action and the determination of the optimal strategies for their use in the clinical setting.
TURIN
EDIZIONI MINERVA MEDICA
0375-9393
179
194
Grant Details
Publication Themes